Jennifer Doudna Questions AI Role in Drug Discovery 14 Years After Crispr Debut

3 articles · Updated · Bloomberg · Jun 24

Jennifer Doudna said AI is unlikely to replace human scientific effort in medical innovation, pushing back on claims that tools like ChatGPT could soon earn credit for discovering drugs.
In a Bloomberg interview, the Crispr pioneer framed the issue as part of a widening debate over how much AI can truly contribute to research rather than just accelerate parts of it.
Doudna’s view carries unusual weight because Crispr-Cas9 transformed biology after its 2012 debut and helped win her the 2020 Nobel Prize in Chemistry.
The comments add skepticism to a broader AI boom that has fueled expectations of rapid breakthroughs in biotech and medicine.

Sources

Left100%

Bloomberg3h ago

Crispr Pioneer Jennifer Doudna Questions AI's Role in Medical Innovation and Drug Discovery

linkedin3h ago

CRISPR A.I. Risks and Consequences | Eric Topol, MD posted on the topic | LinkedIn

innovativegenomics.org3h ago

Jennifer Doudna - Innovative Genomics Institute (IGI)

5 Sources

Nobel laureate Jennifer Doudna is skeptical of AI. Is she a voice of reason or resisting inevitable progress?

Is the AI science revolution a repeat of past tech bubbles, or will it actually accelerate new medical cures?

If an AI designs a flawed drug, who is ultimately responsible—the coder, the doctor, or the machine itself?

Accelerated Science or AI-Driven Drug Discovery? Doudna’s Skepticism, Pharma’s $143B Investment, and the Future of Medicine

Overview

As of June 2026, the scientific landscape is shaped by a dynamic tension between Jennifer Doudna’s push for broad, technology-enabled progress and the pharmaceutical industry’s rapid adoption of AI for targeted drug discovery. Doudna’s influence is seen in the launch of the Doudna supercomputer, a powerful infrastructure supporting diverse scientific challenges at major DOE facilities. Meanwhile, pharma giants are betting on AI to transform specific aspects of drug development, highlighting a split between foundational innovation and application-driven strategies. This debate sets the stage for how technology and human ingenuity will together drive the next wave of medical breakthroughs.

...